GlassScriptPhysician profile
Herold Duroseau
NPI 1811998883
$2,422.91
in general payments reported to CMS, 2019-2025
34 companies · $737 in 2025
The $737 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $50.11 · 2021: $181 · 2022: $346 · 2023: $573 · 2024: $345 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,655.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $264.40 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $236.21 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $169.15 | 2022-2025 | Azstarys |
| Pfizer INC. | $138.67 | 2023-2024 | |
| Luye Pharma (USA) LTD. | $130.00 | 2025 | Erzofri Extended-Release |
| Biomarin Pharmaceutical INC. | $127.22 | 2022-2025 | Voxzogo 1.2mg, Brineura |
| Alkermes, INC. | $125.00 | 2019 | |
| Phathom Pharmaceuticals, INC. | $124.82 | 2025 | Voquezna |
| Ucb, INC. | $89.17 | 2022-2025 | Briviact, Nayzilam |
| Baxter Healthcare | $86.94 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Amphastar Pharmaceuticals, INC. | $80.11 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $77.83 | 2023-2025 | Strensiq, Koselugo |
| Genzyme Corporation | $72.41 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $62.40 | 2019-2023 | Jornay Pm |
| Medtronic, INC. | $59.27 | 2024 | Minimed 780g |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.89 | 2023-2024 | Nucala |
| Novartis Pharmaceuticals Corporation | $47.85 | 2019 | |
| Philips North America LLC | $46.55 | 2025 | Vest Therapy Und |
| Endo USA, INC. | $43.76 | 2024-2025 | Supprelin |
| Acadia Pharmaceuticals INC | $43.53 | 2024 | Daybue |
| Mirum Pharmaceuticals, INC. | $40.78 | 2023-2025 | Livmarli, Cholbam |
| Novo Nordisk INC | $38.93 | 2024-2025 | Sogroya, Rivfloza |
| Tandem Diabetes Care, INC. | $37.35 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $29.28 | 2021 | |
| Celltrion USA INC. | $28.40 | 2025 | Vegzelma |
| Tolmar, INC. | $22.48 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $22.44 | 2024 | |
| Zogenix INC. | $22.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.97 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.24 | 2025 | Triptodur |
| Phadia US INC. | $18.24 | 2023 | Immunocap |
| Jazz Pharmaceuticals INC. | $15.37 | 2022 | |
| Greenwich Biosciences, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herold Duroseau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.